Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT-PET/MRI for early response evaluation to PD-1 inhibitors in NSCLC
jRCTs051180147Completed
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and pembrolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Primary: Association of serial FLT-PET/MRI findings with progression-free survival and tumor response. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180147.